Tradestie Institutional Equity Comparison Engine

RGNX vs ZVRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZVRA Overall Edge

ZVRA Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zevra Therapeutics, Inc. Common Stock (ZVRA) driven by superior Valuation, Growth & Margin, Momentum & Technical while RGNX counters with relative strength in Options & Structure. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus ZVRA at 9.3x Forward P/E and 31.5% operating margin (+44.9% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against ZVRA sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ZVRA
RGNX N/M vs ZVRA 9.3x Fwd P/E
Growth & Margin Winner ZVRA
Op Margin -120.4% vs 31.5% ยท YoY -69.2% vs +44.9%
Momentum & Technical Winner ZVRA
1Y -35.8% vs +0.9% ยท 52W Pos 19% vs 18%
Options & Structure Winner RGNX
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (14th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
1M Return +7.87%
1Y Return -35.82%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
ZVRA NASDAQ
Zevra Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.31
+2.53% 1D
Market Cap $664.1M
1M Return -6.34%
1Y Return +0.87%
Forward P/E 9.3x
Unified AI Score
49.4 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -35.82% ZVRA +0.87% Spread: +36.69 pp (ZVRA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue ZVRA Revenue RGNX Op. Margin ZVRA Op. Margin Margin Edge
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M $10M -422.9% -158.4% ZVRA
FY2020 $150M $10M -77.1% -42.2% ZVRA
FY2021 $470M $30M 34.0% 27.0% RGNX
FY2022 $110M $10M -233.2% -418.9% RGNX
FY2023 $90M $30M -297.1% -180.6% ZVRA
FY2024 $80M $20M -280.0% -368.5% RGNX
FY2025 $170M $110M -94.6% -59.1% ZVRA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (1) vs ZVRA (8)
Institutional Metric RGNX ZVRA Criterion Row Winner
Market Capitalization Scale $500.9M $664.1M Larger Scale ZVRA
Trailing P/E Ratio Valuation N/M 9.7x Lower Multiple ZVRA
Forward P/E Ratio Valuation N/M 9.3x Lower Multiple ZVRA
Revenue Growth (YoY) Growth -69.2% +44.9% Higher Growth ZVRA
Operating Margin (TTM) Profitability -120.4% 31.5% Higher Margin ZVRA
Net Profit Margin Profitability -113.9% 52.8% Higher Margin ZVRA
Return on Equity (ROE) Capital Efficiency -113.2% 41.9% Higher ROE ZVRA
52-Week Range Position Momentum 19% ($5โ€“$16) 18% ($8โ€“$15) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.81ฮฒ ยท 76% Vol 1.18ฮฒ ยท 95% Vol Lower Realized Risk RGNX
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZVRA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs ZVRA Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZVRA BREAKDOWN
111d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live ZVRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor ZVRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.